NCT04445831 - A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

September 5, 2023

Study Completion Date

September 5, 2023

Conditions

Alzheimer's DiseaseCognitive ImpairmentTauopathiesMild Cognitive ImpairmentDementiaBrain DiseasesCentral Nervous System Diseases

Interventions

BIOLOGICAL

ACI-35.030

Administration of a Low dose of ACI-35.030

BIOLOGICAL

ACI-35.030

Administration of a Medium dose of ACI-35.030

BIOLOGICAL

ACI-35.030

Administration of a High dose of ACI-35.030

OTHER

Placebo

Administration of Placebo

BIOLOGICAL

JACI-35.054

Administration of a Low dose of JACI-35.054

BIOLOGICAL

JACI-35.054

Administration of a Medium dose of JACI-35.054

Trial Locations (9)

Clinical Research Services Helsinki, Helsinki

Itä-Suomen Yliopisto - Kuopion Kampus, Kuopio

Clinical Research Services Turku, Turku

Brain Research Center - Den Bosch, 's-Hertogenbosch

Brain Research Center - Amsterdam, Amsterdam

Minnesmottagningen - Sahlgrenska Universitetssjukhuset - Mölndal Sjukhus, Mölndal

Kognitiv Mottagning - Karolinska Universitetssjukhuset - Huddinge, Stockholm

Edinburgh Clinical Research Facility, Edinburgh

University College London Hospitals NHS Foundation Trust, London